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Volume 59, Number 5 Marston 1193DISCUSSIONDr Zachary K. Baldwin (Jackson, Miss). Despite the lack of
high-quality evidence for efﬁcacy, percutaneous access for endovas-
cular aneurysm repair has become commonplace among vascular
interventionalists. In the right hands, it has the potential to miti-
gate the morbidity associated with open groin incision, speed re-
covery, and accelerate discharge. However, in the wrong hands
and without proper training and judgment, there is the potential
for grave complication.
With this in mind and with CMS looking over everyone’s
shoulder in terms of outcomes data and reimbursement, the au-
thors should be commended on putting together a thoughtful
multicenter trial of percutaneous EVAR and traditional EVAR.
The study provides level 1 evidence of noninferiority when
comparing percutaneous to open access. From a clinical stand-
point, PEVAR was found to either trend toward or signiﬁcantly
impact procedure time, time to hemostasis, blood loss, and mean
time to hospital discharge. The study outcomes suggest that
PEVAR has favorable impact on the perioperative course of
EVAR patents. Given the stent graft utilized, French size, and
closure device, these results appear to be applicable to other
EVAR devices on the market.
That being said, the core question of comparative effectiveness
research is which treatment works best, for whom, and under what
circumstances? Answering these questions using this study is some-
what difﬁcult given that the patient cohort is notable for being pre-
dominantly white males with large iliac vessels and average BMIs
<30. The morbidly obese are thought to be a group likely to
beneﬁt from a percutaneous approach. However, it is difﬁcult to
conﬁrm or deny these suspicions based on this particular study.
Iliac morphology may also play a role in deciding between percu-
taneous and open vessel access. It has been my experience that
advancing and withdrawing sheaths in borderline diameter arteries
with signiﬁcant calciﬁcation and/or tortuosity can increase shear at
the level of arteriotomy. Are such cases better approached percuta-
neously, or does open exposure mitigate potential injury?
Finally, one potential beneﬁt of percutaneous access is allow-
ing for an “awake” EVAR. Avoidance of a general anesthetic
should have an impact in terms of perioperative morbidity/mortal-
ity when performing EVAR. Unfortunately, there is little informa-
tion as to whether utilization of PEVAR impacted anesthetic
choice among participating physicians.
Dr Nelson and colleagues should be congratulated on a very
important and timely study that provides much needed evidence
for percutaneous access in performance of EVAR. I do not believe
that the study can be interpreted by interventionalists as a license
to access all patients percutaneously. Instead, the study provides
clear evidence of the percutaneous technique’s safety and will,
hopefully, set the stage for studies in the future deﬁning which pa-
tients beneﬁt most from a percutaneous approach.
Dr Peter R. Nelson. Thank you, Dr Baldwin, for your com-
ments and for your review of our manuscript. I assure you that you
are a candidate for PEVAR. I want to respond to one of the com-
ments that you made. I think we have to be a little careful extrap-
olating these data to all endovascular devices or all large-bore
access procedures since this study was conducted using a singleendovascular stent graft system. I fully realize that people are using
this technique for other systems, but this trial obviously was specif-
ically focused on one device.
With respect to your ﬁrst question on obesity, I think we all
feel that the obese patient is really where the PEVAR technique
could offer the most beneﬁt because the obese suffer the most
morbidity from groin wound complications. But, in designing a
rigorous clinical trial, we have to be cautious upfront because, in
the literature, the obese also have the highest complication rate
of percutaneous access. So in terms of this being the ﬁrst phase
of the trial, it was reasonable to exclusion. The 7-cm distance
required from the skin to the femoral artery was deﬁned by the
length of the micropuncture needle. We felt that if the needle
could not reach the femoral artery easily, then maybe that should
be an anatomic exclusion. We all know that you can indent the skin
and get access in those situations, but at least for the purposes of
the trial, 7 cm was the maximum length allowable.
Regarding your second question on anesthetic options used in
the trial, investigators came into the trial with a certain established
practice or preference in terms of what anesthetic strategy they
used, and we did not see a signiﬁcant change from this baseline
practice. I think that if you were a local anesthetic user before,
you used it in the trial. If you used general anesthetic, you used
it in the trial. We did not see people switching to local anesthesia,
and we did not require or suggest that in PEVAR cases. I think
your point is very important, however, because this technique deﬁ-
nitely opens the door to very feasible use of local anesthetic, which
could result in even shorter hospital stays and even move us toward
outpatient EVAR, and I think that is where we need to be
thinking.
Your third question on iliac morphology is an important ques-
tion. The trial focused most of the exclusion criteria on the com-
mon femoral artery anatomy and calciﬁcation, but we did collect
data on the degree of calciﬁcation in the iliac access vessels. The
amount of calciﬁcation as I showed was similar between groups
and it did not impact the success of the percutaneous access over-
all. Greater calciﬁcation did, however, result in an increased num-
ber of iliac interventions, such angioplasties and adjunctive stenting
for the access vessel. What I do in my practice is if I have someone
who has a heavily calciﬁed iliac access vessel, I still am comfortable
doing percutaneous, but in that case, I might more conservatively
use a series of hydrophilic dilators to sequentially dilate the access
to allow the device to pass. I personally have not had problems
with that affecting the success of percutaneous approach itself.
One additional comment regarding the inﬂuence of iliac anat-
omy is that tortuosity, which we did not critically scientiﬁcally eval-
uate in this trial, is a signiﬁcant variable. If you have a very tortuous
iliac system, and anyone who has done this will know, the Proglide
device is just a little bit short, such that, in a very tortuous iliac sys-
tem, you may have difﬁculty maintaining wire access. If the Pro-
glide device slides back into the iliac system, you have to traverse
that tortuosity twice at least to get the access and secure all of
your preclosure devices. Therefore, iliac tortuosity is something I
think worthy of looking at as you plan cases, since it poses some
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been packaged into smaller and more ﬂexible sheath systems, the
potential for percutaneous aneurysm repair has been realized
with the use of closure devices and speciﬁc pre-closure procedures.In this carefully designed and executed prospective random-
ized trial, the authors have compared standard surgical femoral ac-
cess EVAR (SEVAR) with percutaneous EVAR (PEVAR) using
two different devices designed for femoral artery closure. Sites
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dent Clinical Events Committee adjudicated adverse events. The
data clearly demonstrate that PEVAR is technically feasible, and
with use of the Proglide device, PEVAR was found to be statisti-
cally noninferior to SEVAR with a low incidence of access-
related complications. The study selection criteria excluded
patients with severe calciﬁcation, prior groin incisions, or recent
use of a femoral closure device. The authors do not provide infor-
mation on the frequency with which these criteria might have elim-
inated patients from study consideration, so it is difﬁcult to
determine the proportion of EVAR patients who might be candi-
dates for percutaneous repair.
Although the study results support the technical success
of EVAR with the Proglide device, relatively little evidence is
provided that PEVAR has major advantages over SEVAR. Opera-
tive time for PEVARwas signiﬁcantly shorter, but there were no sig-
niﬁcant differences between PEVAR and SEVAR in pain scores or
quality of life evaluations. Whereas the average time to ambulationand hospital stay were shorter for PEVAR, the differences were not
signiﬁcant and appear to be of minor clinical relevance.
In summary, the results of this study provide strong evidence
that PEVAR can be technically performed with a low incidence of
access-related complications similar to SEVAR. Should PEVAR
become the preferred method for EVAR in appropriate patients?
This would require PEVAR to provide clinically relevant advan-
tages that were not generally demonstrated in this study. It should
also be noted that the study investigators were experienced
vascular specialists familiar with the use of large closure devices.
Some authors have suggested that the learning curve for percuta-
neous access for EVAR requires approximately 30 cases, but the
authors of this manuscript indicate that the learning curve can be
shortened to 5 to 10 cases with the use of simulators and virtual
cases. Regardless, it appears that this procedure would be best per-
formed by high-volume EVAR physicians performing enough
cases to develop and to maintain the skill set to safely perform
this procedure.
